MedTrace Logo

Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial

NCT00583297 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2018-02-22

No results posted yet for this study

Summary

The ABCD clinical study (ClinicalTrials.gov Identifier NCT00187291) was designed to determine if a T-Wave Alternans (TWA) test is equivalent to an Electrophysiology Study (EPS) in predicting life-threatening heart rhythms in patients with ischemic heart disease, left ventricular dysfunction, and non-sustained tachycardia. The purpose of the ABCD Genetic sub-study is to identify genetic markers that predict TWA status and arrhythmia risk in this same population.

Conditions

Sponsors & Collaborators

  • CardioDx

    lead INDUSTRY

Principal Investigators

  • Amy J Sehnert, MD · CardioDx, Inc.

  • Elizabeth Kaufman, MD · MetroHealth Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00583297 on ClinicalTrials.gov